English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/219046
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Automated Synthesis of New Quinoxalinetacrines

AuthorsBautista-Aguilera, Óscar M.; Ismaili, L.; Chioua, Mourad ; Iriepa, Isabel; Martínez-Grau, Angeles; Beadle, C. D.; Vetman, T.; López-Muñoz, Francisco; Marco-Contelles, José
KeywordsFriedländer-type reaction
Lewis acids
Issue Date2020
PublisherChemPubSoc Europe
CitationChemistrySelect 5: 6491-6493 (2020)
AbstractTacrine was the first acetylcholinesterase inhibitor approved for the treatment of Alzheimer's disease although its use has been limited and finally abandoned because of side effects including hepatic toxicity. Based on 1,2,3,4-tetrahydroquinolino[2,3-b]quinoxalin-12-amine (QT78), a recently reported cholinesterase inhibitor, less toxic and potent than tacrine as acetylycholinesterase inhibitor, but more selective against butyrylcholinesterase, herein we report the synthesis of novel quinoxalinetacrines QT1-11, a series of hybrids designed by juxtaposition of tacrine and quinoxaline. The target compounds have been obtained in moderate yields from 3-aminoquinoxaline-2-carbonitrile and suitable commercially available ketones, under microwave-promoted Friedländer reactions catalyzed by aluminium trichloride or indium trichloride. These compounds were synthesized remotely in Eli Lilly's Automated Synthesis Laboratory as part of their Open Innovation Drug Discovery program.
Publisher version (URL)http://dx.doi.org/10.1002/slct.202001593
Identifiersdoi: 10.1002/slct.202001593
issn: 2365-6549
Appears in Collections:(IQOG) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.